| Citation: |
Yang GAO, Zhao SUN, Chun-mei BAI. Application of Immune-checkpoint Inhibitors in Recurrent/Metastatic Nasopharyngeal Carcinoma[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(5): 626-630. DOI: 10.3969/j.issn.1674-9081.2020.05.021
|
Nasopharyngeal carcinoma is mainly associated with Epstein-Barr virus(EBV) infection. The treatment of early nasopharyngeal carcinoma has a good prognosis, but the treatment options for recurrent/metastatic nasopharyngeal carcinoma are limited and the prognosis is poor. In recent years, there have been extensive studies on immunotherapy in advanced nasopharyngeal carcinoma, among which immune-checkpoint inhibitors are effective and causing clinical concern. Programmed death-ligand 1 expression status, tumor mutation burden and circulating EBV-DNA level may be biomarkers for predicting the efficacy of immune-checkpoint inhibitors. The applications of immune-checkpoint inhibitors in recurrent/metastatic nasopharyngeal carcinoma will be reviewed in this article.
| [1] |
Wei KR, Zheng RS, Zhang SW, et al. Nasopharyngeal carcinoma incidence and mortality in China, 2013[J]. Chin J Cancer, 2017,36:90. DOI: 10.1186/s40880-017-0257-9
|
| [2] |
Chua MLK, Wee JTS, Hui EP, et al. Nasopharyngeal carcinoma[J]. Lancet,2016,387:1012-1024. DOI: 10.1016/S0140-6736(15)00055-0
|
| [3] |
Ruuskanen M, Irjala H, Minn H, et al. Epstein-Barr virus and human papillomaviruses as favorable prognostic factors in nasopharyngeal carcinoma: A nationwide study in Finland[J]. Head Neck, 2019,41:349-357. http://www.zhangqiaokeyan.com/academic-journal-foreign-pmc_wiley-blackwell-online-open_thesis/040004934268.html
|
| [4] |
Blanchard P, Lee A, Marguet S, et al. Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis[J]. Lancet Oncol,2015,16:645-655. DOI: 10.1016/S1470-2045(15)70126-9
|
| [5] |
Yang L, Hong SD, Wang Y, et al. Development and External Validation of Nomograms for Predicting Survival in Nasopharyngeal Carcinoma Patients after Definitive Radiotherapy[J]. Sci Rep,2015,5:15638. DOI: 10.1038/srep15638
|
| [6] |
Perri F, Della VSG, Caponigro F, et al. Management of recurrent nasopharyngeal carcinoma: current perspectives[J]. Onco Targets Ther,2019,12:1583-1591. DOI: 10.2147/OTT.S188148
|
| [7] |
Le QT, Colevas AD, O'Sullivan B, et al. Current Treatment Landscape of Nasopharyngeal Carcinoma and Potential Trials Evaluating the Value of Immunotherapy[J]. J Natl Cancer Inst,2019,111:655-663. DOI: 10.1093/jnci/djz044
|
| [8] |
Larbcharoensub N, Mahaprom K, Jiarpinitnun C, et al. Characterization of PD-L1 and PD-1 Expression and CD8+ Tumor-infiltrating Lymphocyte in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma[J]. Am J Clin Oncol, 2018,41:1204-1210. DOI: 10.1097/COC.0000000000000449
|
| [9] |
Walker LSK, Sansom DM. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses[J]. Nat Rev Immunol,2011,11:852-863. DOI: 10.1038/nri3108
|
| [10] |
Chen BJ, Chapuy B, Ouyang J, et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies[J]. Clin Cancer Res,2013,19:3462-3473. DOI: 10.1158/1078-0432.CCR-13-0855
|
| [11] |
Fang WF, Zhang JW, Hong SD, et al. EBV-driven LMP1 and IFN-gamma up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy[J]. Oncotarget,2014,5:12189-12202. DOI: 10.18632/oncotarget.2608
|
| [12] |
Hsu MC, Hsiao JR, Chang KC, et al. Increase of programmed death-1-expressing intratumoral CD8 T cells predicts a poor prognosis for nasopharyngeal carcinoma[J]. Mod Pathol,2010,23:1393-1403. DOI: 10.1038/modpathol.2010.130
|
| [13] |
Xiao M, Qi F, Chen X, et al. Functional polymorphism of cytotoxic T-lymphocyte antigen 4 and nasopharyngeal carcinoma susceptibility in a Chinese population[J]. Int J Immunogenet, 2010,37:27-32. DOI: 10.1111/j.1744-313X.2009.00888.x
|
| [14] |
Hsu C, Lee SH, Ejadi S, et al. Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study[J]. J Clin Oncol,2017,35:4050-4056. DOI: 10.1200/JCO.2017.73.3675
|
| [15] |
Ma B, Lim WT, Goh BC, et al. Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742)[J]. J Clin Oncol, 2018,36:1412-1418. DOI: 10.1200/JCO.2017.77.0388
|
| [16] |
Fang WF, Yang YP, Ma YX, et al. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials[J]. Lancet Oncol,2018,19:1338-1350. DOI: 10.1016/S1470-2045(18)30495-9
|
| [17] |
Zhou YJ, Shi DB, Miao JJ, et al. PD-L1 predicts poor prognosis for nasopharyngeal carcinoma irrespective of PD-1 and EBV-DNA load[J]. Sci Rep,2017,7:43627. DOI: 10.1038/srep43627
|
| [18] |
Fang WF, Zhang JW, Hong SD, et al. EBV-driven LMP1 and IFN-gamma up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy[J]. Oncotarget, 2014,5:12189-12202. DOI: 10.18632/oncotarget.2608
|
| [19] |
Ferris RL, Blumenschein GJ, Fayette J, et al. Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression[J]. Oral Oncol,2018,81:45-51. DOI: 10.1016/j.oraloncology.2018.04.008
|
| [20] |
Harrington KJ, Ferris RL, Blumenschein GJ, et al. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial[J]. Lancet Oncol,2017,18:1104-1115. DOI: 10.1016/S1470-2045(17)30421-7
|
| [21] |
Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial[J]. Lancet Oncol, 2016,17:956-965. DOI: 10.1016/S1470-2045(16)30066-3
|
| [22] |
Liu MB, Han SJ, Zheng B, et al. Cost-Effectiveness Analysis Of Pembrolizumab In The Treatment Of Advanced Recurrent Metastatic Head And Neck Squamous Cell Carcinoma In China And The United States[J]. Cancer Manag Res,2019,11:9483-9493. DOI: 10.2147/CMAR.S226243
|
| [23] |
Cohen EEW, Soulieres D, Le Tourneau C, et al. Pembroli-zumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study[J]. Lancet, 2019,393:156-167. DOI: 10.1016/S0140-6736(18)31999-8
|
| [24] |
Kim KY, Le QT, Yom SS, et al. Clinical Utility of Epstein-Barr Virus DNA Testing in the Treatment of Nasopharyngeal Carcinoma Patients[J]. Int J Radiat Oncol Biol Phys,2017,98:996-1001. DOI: 10.1016/j.ijrobp.2017.03.018
|
| [25] |
Wang WY, Lin TY, Twu CW, et al. Long-term clinical outcome in nasopharyngeal carcinoma patients with post-radiation persistently detectable plasma EBV DNA[J]. Oncotarget,2016,7:42608-42616. http://www.ncbi.nlm.nih.gov/pubmed/27191654
|
| [26] |
Chan ATC, Hui EP, Ngan RKC, et al. Analysis of Plasma Epstein-Barr Virus DNA in Nasopharyngeal Cancer After Chemoradiation to Identify High-Risk Patients for Adjuvant Chemotherapy: A Randomized Controlled Trial[J]. J Clin Oncol,2018.doi: 10.1200/JCO.2018.77.7847.
|
| [27] |
Johnson DB, Frampton GM, Rioth MJ, et al. Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade[J]. Cancer Immunol Res, 2016,4:959-967. DOI: 10.1158/2326-6066.CIR-16-0143
|
| [28] |
Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer[J]. Science,2015,348:124-128. DOI: 10.1126/science.aaa1348
|
| [29] |
Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial[J]. Lancet,2016,387:1909-1920. DOI: 10.1016/S0140-6736(16)00561-4
|
| [30] |
Samstein RM, Lee CH, Shoushtari AN, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types[J]. Nat Genet,2019,51:202-206. DOI: 10.1038/s41588-018-0312-8
|
| [31] |
Brown SD, Warren RL, Gibb EA, et al. Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival[J]. Genome Res,2014,24:743-750. DOI: 10.1101/gr.165985.113
|
| [32] |
Cesano A, Warren S. Bringing the next Generation of Immuno-Oncology Biomarkers to the Clinic[J]. Biomedicines,2018,6:14. DOI: 10.3390/biomedicines6010014
|
| [1] | YAN Xinchun, HUO Li. Evaluation of Von Hippel-Lindau Syndrome Through Novel Small Molecular Tracer 68Ga-NY104 PET/CT Imaging[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(4): 911-915. DOI: 10.12290/xhyxzz.2024-0216 |
| [2] | Zhao-qi WANG, Jia GUO, Ya-nan LU, Hong-kai ZHANG, Hai-liang LI, Jin-rong QU. Application of Magnetic Resonance Imaging in the Preoperative T Staging Evaluation of Resectable Esophageal Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2017, 8(2-3): 112-116. DOI: 10.3969/j.issn.1674-9081.2017.03.006 |
| [3] | Qi ZHANG, Han OUYANG. Diagnostic Value of Magnetic Resonance Imaging for Preoperative Staging of Endometrial Carcinoma[J]. Medical Journal of Peking Union Medical College Hospital, 2017, 8(2-3): 106-111. DOI: 10.3969/j.issn.1674-9081.2017.03.005 |
| [4] | Tian-bin SONG, Jie LU. Diffusion-Weighted Imaging in Neoadjuvant Chemoradiotherapy for Rectal Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2017, 8(2-3): 100-105. DOI: 10.3969/j.issn.1674-9081.2017.03.004 |
| [5] | Sai-hua SUN, Chun-wu ZHOU, Jing LI. The Application of Magnetic Resonance Functional Imaging in Efficacy Assessment of Neoadjuvant Chemotherapy for Breast Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2017, 8(2-3): 95-99. DOI: 10.3969/j.issn.1674-9081.2017.03.003 |
| [6] | Wen-hua LIANG, Jing-jing LU. Magnetic Resonance Imaging Features of Abdominal Wall Endometriosis[J]. Medical Journal of Peking Union Medical College Hospital, 2014, 5(2): 170-174. DOI: 10.3969/j.issn.1674-9081.2014.02.009 |
| [7] | Cheng-jie WANG, Li-chun WU, Qing KANG, Qing LIN. Influence of Artifacts Produced by Two Types of Implants and Porcelain Fused to Metal Crowns on 3.0T Magnetic Resonance Imaging[J]. Medical Journal of Peking Union Medical College Hospital, 2013, 4(1): 35-38. DOI: 10.3969/j.issn.1674-9081.2013.01.008 |
| [8] | Jing GAO, Na NIU, Fang LI, Feng FENG, Zhao-hui ZHU, Xiao-rui HUANG, Bo HOU, Li-ying CUI, Yu-pu GUO. Changes in Parietal Lobe as A Typical Imaging Finding in Patients with Alzheimer's Disease[J]. Medical Journal of Peking Union Medical College Hospital, 2012, 3(3): 265-268. DOI: 10.3969/j.issn.1674-9081.2012.03.004 |
| [9] | Xiao-wei WANG, Dao-feng NI, Ying-ying ZHU, Fang QI, Zhi-qiang GAO, Xiao-wei CHEN. Effectiveness of Betamethasone in Treating Mice with Olfactory Dysfunction from Allergic Rhinitis[J]. Medical Journal of Peking Union Medical College Hospital, 2012, 3(2): 154-161. DOI: 10.3969/j.issn.1674-9081.2012.02.006 |
| [10] | Ming-li LI, Jian ZHANG, Yang LIU, Zheng-yu JIN. Magnetic Resonance Imaging of Sella after Transsphenoidal Resection of Pituitary Macroadenoma[J]. Medical Journal of Peking Union Medical College Hospital, 2011, 2(3): 222-226. DOI: 10.3969/j.issn.1674-9081.2011.03.007 |
| 1. |
胡春华，赵晓艳，吴黎黎，陈红芽，许鑫，王古岩. 术中多模式镇痛对终末期头颈部癌症患者开腹胃造瘘术后早期恢复质量的影响：前瞻性随机对照研究. 协和医学杂志. 2024(02): 359-365 .
 本站查看
| |
| 2. |
安欣璨，赵磊，曹峰，尹春琳，薛张纲，陆智杰，孟庆涛，王锷，徐桂萍，王月兰，雷迁，王天龙. 合并多系统疾病老年患者腹腔镜胰十二指肠切除术的麻醉与围术期管理. 中华麻醉学杂志. 2023(07): 880-883 .
| |
| 3. |
黄重峰，刘毅，程小玲，焦丰，吴文鴶，李铨华. 基于加速康复外科理念的多模式麻醉管理在胸腔镜肺叶切除术围手术期的临床效果. 中国当代医药. 2023(32): 106-109+113 .
| |
| 4. |
张树彬，周新博，胡子轩，邢中强，刘建华. 加速康复外科理念指导腹腔镜肝巨大血管瘤剥除术疗效. 中华肝脏外科手术学电子杂志. 2022(06): 601-606 .
| |
| 5. |
张蕊霞，洪蕾，苏敏君，张楠. 快速康复外科理论下多模式镇痛对腹腔镜全子宫切除术患者应激反应及疼痛的影响. 中国社区医师. 2021(08): 51-52+55 .
| |
| 6. |
郭强，钟锴，蒋铁民，冉博，张瑞青，杨鹏，宋涛，吐尔干艾力·阿吉，邵英梅. 加速康复外科理念在胰十二指肠切除术围手术期中的疗效分析. 中华普外科手术学杂志(电子版). 2020(03): 252-255 .
| |
| 7. |
严晓艳. 快速康复理念下腹腔镜胰十二指肠切除术患者多模式镇痛的护理研究. 心理月刊. 2019(11): 118 .
| |
| 8. |
钟锴，邵英梅. 加速康复外科在胰十二指肠切除术围手术期中的运用. 新疆医学. 2019(09): 857-859+863+849 .
|
Supported by: Beijing Renhe Information Technology Co., Ltd. 
Submit
Review
Office
Email Alert
RSS
DownLoad: